meglumine antimoniate has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abderrahim, E; Bacha, MM; Bahloul, A; Ben Abdallah, T; Ben Maïz, H; Chaouech, D; Cherif, M; Khaled, S; Kheder, A; Ounissi, M; Rajhi, H; Trabelsi, S; Turki, S; Znaidi, N | 1 |
| Gholami, E; Habibzadeh, S; Heidari-Kharaji, M; Khadir, F; Oryan, A; Rafati, S; Taheri, T; Zahedifard, F | 1 |
2 other study(ies) available for meglumine antimoniate and sirolimus
| Article | Year |
|---|---|
[Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney transplantation].
Topics: Adult; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antiprotozoal Agents; Antiviral Agents; Epstein-Barr Virus Infections; Ganciclovir; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leishmaniasis, Visceral; Lymphoproliferative Disorders; Male; Meglumine; Meglumine Antimoniate; Opportunistic Infections; Organometallic Compounds; Postoperative Complications; Remission Induction; Rituximab; Sirolimus | 2011 |
Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cytokines; Female; Humans; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Lymph Nodes; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Parasite Load; Random Allocation; Sirolimus; TOR Serine-Threonine Kinases | 2019 |